Novartis Buys Right to Anti-Smoking Drug
Forbes has a report on Novartis purchasing the rights to NicQb, an anti-smoking vaccine from Cytos Biotechnology AG up to $500 million. The initial upfront payment is $29 million.
Novartis Buys Right to Experimental Drug - Forbes.com:
It will be interesting to watch and see how NicQb comes along. Currently it is in phase II studies but if successful could be a huge success. To my knowledge, this is the only vaccine being developed to combat nicotine addition.
Technorati Tags: anti-smoking vaccine, Cytos Biotechnology, NicQb, Novartis
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
